摘要
目的 探讨乳腺癌患者血清催乳素、糖类抗原50(CA50)和CA15-3表达水平与疾病发生发展的关系。方法 回顾性选取2018年10月至2021年1月间青岛市中心医院收治的120例乳腺癌患者为观察组,另选取同期健康体检志愿者120例为对照组,比较两组受试者及观察组患者不同病理状态的血清中催乳素、CA50和CA15-3表达水平,分析三者表达水平与疾病发生发展的关系。结果 观察组患者血清催乳素、CA50和CA15-3水平均高于对照组,差异均有统计学意义(均P<0.05)。不同肿瘤直径、TNM分期、淋巴结转移、脉管转移、雌激素和孕激素患者的催乳素、CA50和CA15-3水平之间比较,差异均有统计学意义(均P<0.05)。相关性分析显示,患者肿瘤直径、TNM分期、淋巴结转移、脉管转移、雌激素和孕激素受体不同情况与催乳素、CA50和CA15-3水平均呈正相关(均P<0.05)。结论 催乳素、CA50和CA15-3水平与乳腺癌患者的疾病进展呈相关性,可作为疾病进展预测的重要依据。
Objective To study the relationship between the expression level of prolactin, CA50 and CA15-3 and disease development in breast cancer patients. Methods In this study, 120 patients with breast cancer treated at Qingdao Central Hospital were selected and included in an observation group from October 2018 to January 2021. Another 120 healthy volunteers were selected and included in a control group. The differences in serum prolactin, CA50 and CA15-3 levels were compared between the two groups of different pathological states. The relationship between the expression levels of these three serum factors and disease development was analyzed. Results The levels of prolactin, CA50 and CA15-3 were significantly higher in the observation group than those in the control group(all P<0.05). There were significant differences in prolactin, CA50 and CA15-3 levels among patients with different tumor diameter, TNM stage, lymph node metastasis, vascular metastasis, estrogen and progesterone(all P<0.05). Moreover, correlation analysis showed tumor diameter, TNM stage, lymph node metastasis, vascular metastasis, estrogen and progesterone were positively correlated with prolactin, CA50 and CA15-3 levels(all P<0.05). Conclusion The level of prolactin, CA50 and CA15-3 were associated with the progression of breast cancer, and can be used as an important basis for the prediction of disease progression.
作者
张雁
刘松岭
周爱凤
王志群
ZHANG Yan;LIU Song-ling;ZHOU Ai-feng;WANG Zhi-qun(Department of Laboratory Medicine,Qingdao Central Hospital,Qingdao 266000,China;Department of Breast Surgery,Qingdao Central Hospital,Qingdao 266000,China)
出处
《中国肿瘤临床与康复》
2022年第4期412-415,共4页
Chinese Journal of Clinical Oncology and Rehabilitation